-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28

Benzinga·05/20/2026 16:02:24
Listen to the news
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price target from $25 to $28.